Octreotide vs lanreotide: evidence, cost, and legality

Which is better, octreotide or lanreotide?

Both have human RCT evidence and full FDA approval, and in the acromegaly meta-analysis their hormone control rates were in the same range (octreotide LAR about 57% for growth hormone and 67% for IGF-1, lanreotide about 48% and 47%, across heterogeneous studies). Octreotide is more flexible (subcutaneous, depot, and oral forms) and has cheaper generic short acting versions. Lanreotide's CLARINET evidence extends to pancreatic neuroendocrine tumors and higher Ki-67 grade 2 tumors, while PROMID studied midgut tumors only, and its prefilled syringe allows self injection. No large randomized head-to-head trial is cited here. [1] [2] [4] [5] [6]

How do octreotide and lanreotide compare?

Octreotide and Lanreotide compared by dimension
Dimension	Octreotide	Lanreotide
Formulations [5] [6]	Subcutaneous injection two to four times daily (Sandostatin, Bynfezia), intramuscular depot every 4 weeks (Sandostatin LAR), and oral delayed release capsules (Mycapssa).	Deep subcutaneous depot every 4 weeks (Somatuline Depot, generic lanreotide), with extended 6 to 8 week intervals possible in controlled acromegaly.
Neuroendocrine tumor trial [1] [4]	PROMID (85 patients, midgut tumors, LAR 30 mg monthly): median time to progression 14.3 versus 6.0 months, hazard ratio 0.34.	CLARINET (204 patients, enteropancreatic grade 1 or 2 tumors with Ki-67 under 10%, 120 mg monthly): progression free survival hazard ratio 0.47; 65.1% versus 33.0% progression free at 24 months.
Note: The trials enrolled different tumor populations, so the hazard ratios should not be compared directly. Neither showed an overall survival difference.
Acromegaly control [2]	Octreotide LAR normalized growth hormone in about 57% and IGF-1 in about 67% of patients in the pooled analysis.	Lanreotide normalized growth hormone in about 48% and IGF-1 in about 47% of patients in the same pooled analysis.
Note: The pooled studies differed in patient selection; octreotide results were higher in preselected responders.
FDA approvals [5] [6]	1988 (acromegaly, carcinoid tumors, VIPomas); LAR 1998; Bynfezia and Mycapssa 2020. Generic injection and depot available.	2007 (acromegaly), 2014 (gastroenteropancreatic neuroendocrine tumors), 2017 (carcinoid syndrome). Generic approved December 2021.
Note: Lanreotide carries a labeled antiproliferative indication for GEP-NETs; octreotide's antitumor use rests on PROMID and guidelines.
Gastrointestinal and gallbladder effects [3] [4]	Diarrhea, nausea, abdominal pain, and steatorrhea in up to 30 to 60% in acromegaly trials; gallstones or sludge in up to about half on long term treatment, mostly asymptomatic.	Diarrhea 26% versus 9% placebo and cholelithiasis 10% versus 3% in CLARINET; abdominal pain 14%.
Administration [5] [6]	LAR is a deep intramuscular gluteal injection given in clinic; short acting forms are self injected several times daily.	Prefilled syringe for deep subcutaneous injection into the upper outer buttock, which the Somatuline Depot label says is intended for administration by a healthcare provider.
Typical cost [5] [6]	Generic subcutaneous octreotide roughly 200 to 800 USD per month cash; Sandostatin LAR roughly 4,000 to 8,000 USD per injection at list.	Somatuline Depot roughly 6,000 to 9,000 USD per injection at list; generic lanreotide lower but still several thousand USD.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Octreotide and Lanreotide: grade, status, and cost
Attribute	Octreotide	Lanreotide
Class	Synthetic cyclic octapeptide analog of somatostatin (somatostatin receptor 2 and 5 agonist)	Synthetic cyclic octapeptide analog of somatostatin (somatostatin receptor 2 and 5 agonist), long acting depot
What it is	FDA approved since 1988 for acromegaly and carcinoid syndrome; the randomized PROMID trial showed it slows midgut neuroendocrine tumor growth (HR 0.34).	FDA approved monthly copy of the hormone somatostatin for acromegaly and neuroendocrine tumors; halved tumor progression risk in the CLARINET trial (HR 0.47).
Evidence	Evidence: Human RCT evidence	Evidence: Human RCT evidence
FDA status	Regulatory: FDA approved	Regulatory: FDA approved
Compounding	FDA approved as Sandostatin injection in 1988 (acromegaly, carcinoid tumors, VIPomas), Sandostatin LAR depot in 1998, Bynfezia Pen in 2020, and Mycapssa oral capsules in 2020 for acromegaly. Generic octreotide injection and generic depot products are available. Compounding is limited to patient specific needs because approved products exist.	FDA approved as Somatuline Depot in August 2007 for acromegaly, December 2014 for unresectable gastroenteropancreatic neuroendocrine tumors, and September 2017 for carcinoid syndrome. A generic lanreotide injection was approved in December 2021. Compounding is not permitted beyond patient specific exceptions because approved products exist.
WADA	WADA: Not WADA prohibited	WADA: Not WADA prohibited
Routes	Subcutaneous injection two to four times daily (Sandostatin, Bynfezia), Intramuscular depot every 4 weeks (Sandostatin LAR), Oral delayed release capsule (Mycapssa), Intravenous infusion (hospital use, for example variceal bleeding off label)	Deep subcutaneous injection every 4 weeks (prefilled syringe, can be self administered or given by a caregiver)
Typical cost	Generic subcutaneous octreotide runs roughly 200 to 800 USD per month at cash prices depending on dose. Sandostatin LAR lists at roughly 4,000 to 8,000 USD per monthly injection, with generic depot products somewhat lower. Insurance and Medicare Part B or D typically cover it for approved indications.	Brand Somatuline Depot lists at roughly 6,000 to 9,000 USD per monthly injection; generic lanreotide is lower but still several thousand USD. Insurance and Medicare Part B or D typically cover it for approved indications, and a manufacturer assistance program exists.
Last verified	Sep 23, 2026	Sep 23, 2026

Has octreotide been tested directly against lanreotide?

No published trial has compared octreotide and lanreotide directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do octreotide and lanreotide cost?

Typical cost of Octreotide and Lanreotide
Dimension	Octreotide	Lanreotide
Typical cost	Generic subcutaneous octreotide runs roughly 200 to 800 USD per month at cash prices depending on dose. Sandostatin LAR lists at roughly 4,000 to 8,000 USD per monthly injection, with generic depot products somewhat lower. Insurance and Medicare Part B or D typically cover it for approved indications.	Brand Somatuline Depot lists at roughly 6,000 to 9,000 USD per monthly injection; generic lanreotide is lower but still several thousand USD. Insurance and Medicare Part B or D typically cover it for approved indications, and a manufacturer assistance program exists.
Price detail	Price index in progress	Price index in progress

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Is lanreotide better than octreotide for neuroendocrine tumors?

They have not been compared in a large randomized trial. Each beat placebo in its own trial, PROMID for midgut tumors and CLARINET for intestinal and pancreatic tumors, but the populations differed. Guidelines treat them as broadly interchangeable, with the choice driven by tumor site, formulation, and coverage. [1] [4]

Can I switch between them?

Both act on somatostatin receptors 2 and 5, and their labels support monthly maintenance dosing, so switching is common in practice, for example to move from a clinic intramuscular injection to home subcutaneous injections. The prescriber sets the equivalent dose and monitors hormone levels or tumor response. [5] [6]

Is there an oral option?

Only for octreotide. Mycapssa oral delayed release capsules were approved in 2020 for acromegaly maintenance. Lanreotide is injection only. [5]

What side effects do they share?

Both commonly cause diarrhea, abdominal pain, and gallstones or biliary sludge, can raise or lower blood sugar, and can slow heart rate. In CLARINET, diarrhea affected 26% and gallstones 10% of lanreotide patients. [3] [4] [6]

Are they available from compounding pharmacies or peptide clinics?

No. Both are FDA approved with generic versions, so compounding is limited to patient specific exceptions. They are prescribed by endocrinologists and oncologists and dispensed through specialty pharmacies or given in clinic. [5] [6]

Conditions studied

Acromegaly

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 23). Octreotide vs lanreotide: evidence, cost, and legality. https://peptideagent.ai/compare/octreotide-vs-lanreotide
HTML link: <a href="https://peptideagent.ai/compare/octreotide-vs-lanreotide">Octreotide vs lanreotide: evidence, cost, and legality</a>, PeptideAgent, updated September 23, 2026.

Octreotide vs lanreotide

The short answer